Peptide Therapeutics Market Size
| Study Period | 2021 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 9.66 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Peptide Therapeutics Market Analysis
The peptide therapeutics market is expected to register a CAGR of 9.66% over the forecast period.
The COVID-19 pandemic substantially impacted the peptide therapeutics market. The pandemic surged the need for the development of novel peptides. In April 2022, an article published in the IJPRT journal reported the companies had developed peptide-based vaccines for COVID-19 treatment. Thus, initially, the growth of the peptide therapeutics market was driven by the increase in COVID-19 cases, as peptide therapeutics were reported efficacious for the treatment of Sars-CoV-2 infection. However, in the current scenario, as the pandemic has declined, the market may get negatively impacted. However, it is anticipated that with the efficacy of peptide therapeutics in treating other chronic diseases, the studied market will witness stable growth over the forecast period.
The major factors driving the market growth are the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements in peptide therapeutics.
Cancer cases are increasing worldwide. Globocan 2020 reported that by 2040, cancer cases worldwide are expected to increase by 56.7% of the current cancer cases. Studies have reported the significant results of peptide therapeutics in cancer treatment. For instance, in February 2021, an article published in the journal SCB reported that new-generation peptide therapeutics target cancer-specific signatures. Hence, they hold enormous potential for cancer therapy and diagnosis. Therefore, the increasing number of cancer cases and the significant effect of peptide therapeutics in cancer treatment is driving the growth of the studied market.
Also, the rising prevalence of some metabolic disorders, such as genetic disorders, organ dysfunction, and mitochondrial dysfunction, is fueling the growth of the studied market. Gaucher disease (GD) is an autosomal recessive lysosomal storage disorder characterized by progressive glucocerebroside storage in macrophages, predominantly in bone, bone marrow, liver, and spleen. In July 2022, an article published in the journal JPHO asserted that the prevalence of GD in global birth was 1.5 cases per 100,000 live births. The overall global prevalence of GD was 0.9 cases per 100,000 inhabitants. The high prevalence of such metabolic disorders is fueling the demand for peptide therapeutics for treating metabolic disorders, thereby driving the growth of the studied market.
Furthermore, the technological development and introduction of new peptide therapeutics for treating chronic diseases like cancer are also fueling the growth of the studied market. In May 2021, ISSAR Pharmaceuticals decided to license out its peptide-based new NCEs with pre-IND filing and the United States patent for various unmet healthcare needs of the population, making it affordable and accessible for better health outcomes. Such developments are driving the growth of the studied market.
Therefore, the studied market is expected to witness significant growth over the forecast period due to the increasing prevalence of cancer and metabolic disorders, rising investments in research and development of novel drugs, and technological advancements. However, instability issues of peptide therapeutics, the high cost of developing drugs, and stringent regulatory requirements for drug approval are expected to restrain the market growth.
Peptide Therapeutics Market Trends
This section covers the major market trends shaping the Peptide Therapeutics Market according to our research experts:
Cancer Segment Expected to Witness Significant Growth
The cancer segment is expected to witness significant growth over the forecast period. Peptide therapeutics are targeted in drug delivery for cancer due to their high specificity, discernment, small sizes, ease of modification, and high biocompatibility. Factors such as the growing burden of cancer, the launch of products, and research and development are driving the segment's growth.
The increasing frequency of cancer globally and increasing prescription of peptide therapeutics for cancer treatment are the key factors responsible for the dominance of this segment. For instance, in the Cancer Facts & Figures 2022 data published by the American Cancer Society, an estimated 1.9 million new cancer cases will be diagnosed in the US in 2022. Thus, the high prevalence of cancer cases globally is expected to play a vital role in the growth of the studied segment over the forecast period.
Furthermore, technological developments and new product launches are fueling the studied market's growth. In March 2022, BioNTech SE reported the expansion of its strategic collaboration with Regeneron to advance the Company's FixVaccandidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor, in advanced non-small cell lung cancer (NSCLC). Under the terms of the agreement, the companies plan to jointly conduct clinical trials to evaluate their combination in different patient populations with advanced NSCLC.
Moreover, the funding and investments for developing cancer vaccines are fueling this segment's growth. In September 2022, the Gastro-Intestinal Research Foundation (GIRF) in Chicago granted ElicioTherapeutics a USD 2.8 million grant to fund research for two therapeutic cancer vaccines. ELI-007 is being developed to target BRAF gene mutations, whereas ELI-008 is being designed to target p53 hotspot mutations in solid tumors, such as colorectal cancer, melanoma, and non-small cell lung cancer (NSCLC).
Thus, the segment is expected to witness significant growth over the forecast period due to the increasing number of cancer cases, technological developments, and the efficiency of peptide therapeutics in cancer treatment.
North America Expected to Witness Significant Growth
North America is expected to dominate the overall market throughout the forecast period. The market growth is due to various crucial factors, such as increased awareness levels relating to peptide therapeutic products, the increasing necessity for diagnostics in cancer and other diseases, and the developing biotechnology industry.
The high incidence of diseases such as cancer, CVDs, and diabetes creates demand for new biopharmaceuticals in the country. For instance, as per the Canadian Cancer Statistics 2021 released in November 2021, an estimated 229,200 Canadians were diagnosed with cancer. Thus, such high numbers of cancer cases are creating opportunities for new peptide therapeutics in the country and driving the studied market.
The rising prevalence of chronic diseases among the Mexican population is also expected to drive the market's growth. For instance, the IDF published in December 2021 estimated 14 million adults in Mexico living with diabetes. Peptides like amide (GLP-1) are effective in diabetes treatment. This is expected to raise the demand for peptide therapeutics, thereby contributing to the growth of the market in the region over the forecast period.
Furthermore, the rising government initiatives are also driving the growth of the studied market in the region. For instance, in February 2022, the Government of Nova Scotia province reported that Nova Scotians enrolled in Pharmacare programs that will begin switching to a biosimilar version of certain biologic drugs, including some insulins and medications, for treating Crohn's disease and rheumatism. More than 10,000 Canadians have safely switched to a biosimilar as part of this initiative. The increasing population using biosimilar drugs is also expected to contribute to the growth of the market in the region.
Thus, the rising awareness levels relating to peptide therapeutic products, technological advancements due to the presence of key market players, and rising cases of chronic diseases like cancer and diabetes are driving the growth of this market in the region over the forecast period.
Peptide Therapeutics Industry Overview
The peptide therapeutics market is highly competitive and fragmented, consisting of several major players. Some of the companies currently dominating the market are Eli Lilly and Company, Amgen Inc., Pfizer Inc., Bristol-Myers Squibb Company, Ever Neuro Pharma GmbH, Takeda Pharmaceutical Company Limited, Teva Pharmaceuticals Industries Ltd, AstraZeneca PLC, GlaxoSmithKline PLC, Novo Nordisk AS, Novartis AG, Zealand Pharma AG, and SELLAS Life Sciences Group (Galena Biopharmaceuticals).
Peptide Therapeutics Market Leaders
Eli Lilly and Company
Amgen Inc.
Bristol-Myers Squibb Company
GlaxoSmithKline PLC
AstraZeneca PLC
*Disclaimer: Major Players sorted in no particular order
Peptide Therapeutics Market News
- November 2022: Enterome developed one of the first-in-class immunomodulatory drugs based on its bacterial mimicry drug discovery platform. Enterome reported the safety, immunogenicity, and efficacy data of its Phase 1/2 clinical trial of EO2401, in combination with an immune checkpoint inhibitor, for treating patients with first progression/recurrence of glioblastoma (ROSALIE trial).
- September 2022: The life science group Sartorius, through its French-listed subgroup Sartorius StedimBiotech, acquired Albumedix Ltd. Albumedix is one of the key players in the field of recombinant albumin-based solutions.
Peptide Therapeutics Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions & Market Definition
1.2 Scope Of The Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Cancer and Metabolic Disorders
4.2.2 Rising Investments in Research and Development of Novel Drugs
4.2.3 Technological Advancements
4.3 Market Restraints
4.3.1 Instability of Peptides
4.3.2 High Cost of Developing Drugs and Stringent Regulatory Requirements for Drug Approval
4.4 Industry Attractiveness - Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD Million)
5.1 By Marketing Type
5.1.1 Generic
5.1.2 Branded
5.2 By Application
5.2.1 Gastrointestinal Disorders
5.2.2 Neurological Disorders
5.2.3 Metabolic Disorders
5.2.4 Cancer
5.2.5 Other Applications
5.3 By Route of Administration
5.3.1 Parenteral
5.3.2 Oral
5.3.3 Other Routes of Administration
5.4 By Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Amgen Inc.
6.1.3 Pfizer Inc.
6.1.4 Bristol-Myers Squibb Company
6.1.5 Ever Neuro Pharma GmbH
6.1.6 Takeda Pharmaceutical Company Limited
6.1.7 Teva Pharmaceuticals Industries Ltd
6.1.8 AstraZeneca PLC
6.1.9 GlaxoSmithKline PLC
6.1.10 Novo Nordisk AS
6.1.11 Novartis AG
6.1.12 Zealand Pharma AG
6.1.13 SELLAS Life Sciences Group (Galena Biopharmaceuticals)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Peptide Therapeutics Industry Segmentation
Peptides are short chains of amino acid monomers linked by peptide bonds. Peptides are distinguished from proteins based on size and, as a benchmark, can be understood to contain approximately 50 amino acids or less.
The Peptide Therapeutics Market is Segmented by Marketing Type (Generic and Branded), Application (Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications), Route of Administration (Parenteral, Oral, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (USD million) for all the above segments.
| By Marketing Type | |
| Generic | |
| Branded |
| By Application | |
| Gastrointestinal Disorders | |
| Neurological Disorders | |
| Metabolic Disorders | |
| Cancer | |
| Other Applications |
| By Route of Administration | |
| Parenteral | |
| Oral | |
| Other Routes of Administration |
| By Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Peptide Therapeutics Market Research FAQs
What is the current Peptide Therapeutics Market size?
The Peptide Therapeutics Market is projected to register a CAGR of 9.66% during the forecast period (2024-2029)
Who are the key players in Peptide Therapeutics Market?
Eli Lilly and Company, Amgen Inc., Bristol-Myers Squibb Company, GlaxoSmithKline PLC and AstraZeneca PLC are the major companies operating in the Peptide Therapeutics Market.
Which is the fastest growing region in Peptide Therapeutics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Peptide Therapeutics Market?
In 2024, the North America accounts for the largest market share in Peptide Therapeutics Market.
What years does this Peptide Therapeutics Market cover?
The report covers the Peptide Therapeutics Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Peptide Therapeutics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
What are the key challenges hindering the growth of the Peptide Therapeutics Market?
The key challenges hindering the growth of the Peptide Therapeutics Market are a) High production costs b) Complex manufacturing processes c) Limited commercialization of peptide drugs
Peptide Therapeutics Industry Report
The Peptide Therapeutics industry is experiencing remarkable growth, fueled by the rising prevalence of chronic diseases like cancer and metabolic disorders, driving demand for innovative treatments. Advancements in delivery technologies, such as PEGylation and the development of oral peptide therapies, are enhancing drug efficacy and patient compliance. Significant investments in R&D are leading to novel peptide-based drugs, with cancer and metabolic disorders segments witnessing substantial growth due to the effectiveness of peptides in targeted drug delivery. The industry benefits from advancements in synthesis and manufacturing processes, addressing production challenges. With a focus on innovation and meeting unmet medical needs, the Peptide Therapeutics market is set for continued expansion, offering promising opportunities for market players and better patient outcomes. For detailed market share, size, and revenue growth rate, refer to Mordor Intelligence™ Industry Reports, providing a comprehensive analysis and forecast outlook of the Peptide Therapeutics market, available as a free report PDF download.
